Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition

Science Translational Medicine

Volumn 5, Issue 179, 2013, Pages

  Uslaner, Jason M ^a   Tye, Spencer J ^a   Eddins, Donnie M ^a,b   Wang, Xiaohai ^a   Fox, Steven V ^a   Savitz, Alan T ^a   Binns, Jacquelyn ^a   Cannon, Christopher E ^a   Garson, Susan L ^a   Yao, Lihang ^a   Hodgson, Robert ^a   Stevens, Joanne ^a   Bowlby, Mark R ^a   Tannenbaum, Pamela L ^a   Brunner, Joseph ^a   McDonald, Terrence P ^a   Gotter, Anthony L ^a   Kuduk, Scott D ^a   Coleman, Paul J ^a   Winrow, Christopher J ^a   Renger, John J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; DIAZEPAM; DORA 22; DUAL OREXIN RECEPTOR ANTAGONIST; ESZOPICLONE; HYPNOTIC SEDATIVE AGENT; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PROTEIN INHIBITOR; SCOPOLAMINE; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARC GENE; ARTICLE; ATTENTION DISTURBANCE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG TOLERABILITY; GENE; INSOMNIA; MEMORY DISORDER; NERVE CELL PLASTICITY; NEUROLOGIC EXAMINATION; NEUROMODULATION; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REACTION TIME; RHESUS MONKEY; SLEEP INDUCTION; STANDARD; TREATMENT RESPONSE; WORKING MEMORY;

ADMINISTRATION, ORAL; ANIMALS; ATTENTION; AZABICYCLO COMPOUNDS; CHOICE BEHAVIOR; COGNITION; CYTOSKELETAL PROTEINS; DIAZEPAM; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HYPNOTICS AND SEDATIVES; MACACA MULATTA; MALE; MEMORY, SHORT-TERM; NERVE TISSUE PROTEINS; PIPERAZINES; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; RECOGNITION (PSYCHOLOGY); SLEEP; TASK PERFORMANCE AND ANALYSIS; TIME FACTORS; TRIAZOLES;

EID: 84876001969     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005213     Document Type: Article

References (70)

1. J. K. Walsh, C. L. Engelhardt, The direct economic costs of insomnia in the United States for 1995. Sleep 22 (Suppl. 2), S386-S393 (1999).
2. M. M. Ohayon, Prevalence of DSM-IV diagnostic criteria of insomnia: Distinguishing insomnia related to mental disorders from sleep disorders. J. Psychiatr. Res. 31, 333-346 (1997).
3. M. M. Ohayon, P. Lemoine, V. Arnaud-Briant, M. Dreyfus, Prevalence and consequences of sleep disorders in a shift worker population. J. Psychosom. Res. 53, 577-583 (2002).
4. S. Weyerer, H. Dilling, Prevalence and treatment of insomnia in the community: Results from the Upper Bavarian Field Study. Sleep 14, 392-398 (1991).
5. G. E. Simon, M. VonKorff, Prevalence, burden, and treatment of insomnia in primary care. Am. J. Psychiatry 154, 1417-1423 (1997).
6. I. Berlin, D. Warot, T. Hergueta, P. Molinier, C. Bagot, A. J. Puech, Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J. Clin. Psychopharmacol. 13, 100-106 (1993).
7. P. Danjou, I. Paty, R. Fruncillo, P. Worthington, M. Unruh, W. Cevallos, P. Martin, A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br. J. Clin. Pharmacol. 48, 367-374 (1999).
8. I. Hindmarch, A. Patat, N. Stanley, I. Paty, U. Rigney, Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum. Psychopharmacol. 16, 159-167 (2001).
9. S. Otmani, A. Demazières, C. Staner, N. Jacob, T. Nir, N. Zisapel, L. Staner, Effects of prolongedrelease melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol. 23, 693-705 (2008).
10. C. R. Rush, D. L. Armstrong, J. A. Ali, P. J. Pazzaglia, Benzodiazepine-receptor ligands in humans: Acute performance-impairing, subject-rated and observer-rated effects. J. Clin. Psychopharmacol. 18, 154-165 (1998).
11. T. Roth, K. M. Hartse, F. J. Zorick, M. E. Kaffeman, The differential effects of short- and long-acting benzodiazepines upon nocturnal sleep and daytime performance. Arzneimittelforschung 30, 891-894 (1980).
12. G. Darcourt, D. Pringuey, D. Sallière, J. Lavoisy, The safety and tolerability of zolpidem - An update. J. Psychopharmacol. 13, 81-93 (1999).
13. H. Allain, D. Bentué-Ferrer, S. L. Breton, E. Polard, J. M. Gandon, Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. Hum. Psychopharmacol. 18, 369-374 (2003).
14. I. Hindmarch, E. Legangneux, N. Stanley, S. Emegbo, J. Dawson, A double-blind, placebocontrolled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br. J. Clin. Pharmacol. 62, 538-545 (2006).
15. E. Weinling, S. McDougall, F. Andre, G. Bianchetti, C. Dubruc, Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam. Clin. Pharmacol. 20, 397-403 (2006).
16. F. Barbone, A. D. McMahon, P. G. Davey, A. D. Morris, I. C. Reid, D. G. McDevitt, T. M. MacDonald, Association of road-traffic accidents with benzodiazepine use. Lancet 352, 1331-1336 (1998).
17. M. Partinen, K. Hirvonen, C. Hublin, M. Halavaara, H. Hiltunen, Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med. 4, 553-561 (2003).
18. J. C. Verster, E. R. Volkerts, A. H. Schreuder, E. J. Eijken, J. H. van Heuckelum, D. S. Veldhuijzen, M. N. Verbaten, I. Paty, M. Darwish, P. Danjou, A. Patat, Residual effects of middle-of-thenight administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J. Clin. Psychopharmacol. 22, 576-583 (2002).
19. J. C. Verster, D. S. Veldhuijzen, E. R. Volkerts, Residual effects of sleep medication on driving ability. Sleep Med. Rev. 8, 309-325 (2004).
20. J. C. Verster, D. S. Veldhuijzen, A. Patat, B. Olivier, E. R. Volkerts, Hypnotics and driving safety: Meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr. Drug Saf. 1, 63-71 (2006).
21. J. C. Verster, E. R. Volkerts, B. Olivier, W. Johnson, L. Liddicoat, Zolpidem and traffic safety - The importance of treatment compliance. Curr. Drug Saf. 2, 220-226 (2007).
22. R. A. España, T. E. Scammell, Sleep neurobiology from a clinical perspective. Sleep 34, 845-858 (2011).
23. T. E. Scammell, C. J. Winrow, Orexin receptors: Pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 51, 243-266 (2011).
24. D. B. Whitman, C. D. Cox, M. J. Breslin, K. M. Brashear, J. D. Schreier, M. J. Bogusky, R. A. Bednar, W. Lemaire, J. G. Bruno, G. D. Hartman, D. R. Reiss, C. M. Harrell, R. L. Kraus, Y. Li, S. L. Garson, S. M. Doran, T. Prueksaritanont, C. Li, C. J. Winrow, K. S. Koblan, J. J. Renger, P. J. Coleman, Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an N,N-disubstituted- 1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 4, 1069-1074 (2009).
25. C. J. Winrow, A. L. Gotter, C. D. Cox, S. M. Doran, P. L. Tannenbaum, M. J. Breslin, S. L. Garson, S. V. Fox, C. M. Harrell, J. Stevens, D. R. Reiss, D. Cui, P. J. Coleman, J. J. Renger, Promotion of sleep by suvorexant - A novel dual orexin receptor antagonist. J. Neurogenet. 25, 52-61 (2011).
26. P. Bettica, G. Nucci, C. Pyke, L. Squassante, S. Zamuner, E. Ratti, R. Gomeni, R. Alexander, Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J. Psychopharmacol. 26, 1058-1070 (2012).
27. P. Bettica, L. Squassante, J. A. Groeger, B. Gennery, R. Winsky-Sommerer, D. J. Dijk, Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37, 1224-1233 (2012).
28. L. de Lecea, T. S. Kilduff, C. Peyron, X. Gao, P. E. Foye, P. E. Danielson, C. Fukuhara, E. L. Battenberg, V. T. Gautvik, F. S. Bartlett II, W. N. Frankel, A. N. van den Pol, F. E. Bloom, K. M. Gautvik, J. G. Sutcliffe, The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327 (1998).
29. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R. M. Chemelli, H. Tanaka, S. C. Williams, J. A. Richardson, G. P. Kozlowski, S. Wilson, J. R. Arch, R. E. Buckingham, A. C. Haynes, S. A. Carr, R. S. Annan, D. E. McNulty, W. S. Liu, J. A. Terrett, N. A. Elshourbagy, D. J. Bergsma, M. Yanagisawa, Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585 (1998).
30. C. Peyron, D. K. Tighe, A. N. van den Pol, L. de Lecea, H. C. Heller, J. G. Sutcliffe, T. S. Kilduff, Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015 (1998).
31. P. J. Coleman, J. D. Schreier, C. D. Cox, M. J. Breslin, D. B. Whitman, M. J. Bogusky, G. B. McGaughey, R. A. Bednar, W. Lemaire, S. M. Doran, S. V. Fox, S. L. Garson, A. L. Gotter, C. M. Harrell, D. R. Reiss, T. D. Cabalu, D. Cui, T. Prueksaritanont, J. Stevens, P. L. Tannenbaum, R. G. Ball, J. Stellabott, S. D. Young, G. D. Hartman, C. J. Winrow, J. J. Renger, Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5- methyl-2-(pyrimidin- 2-yl)phenyl]methanone (MK-6096): A dual orexin receptor antagonist with potent sleeppromoting properties. ChemMedChem 7, 415-424 (2012).
32. J. F. Guzowski, B. L. McNaughton, C. A. Barnes, P. F. Worley, Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles. Nat. Neurosci. 2, 1120-1124 (1999).
33. J. F. Guzowski, G. L. Lyford, G. D. Stevenson, F. P. Houston, J. L. McGaugh, P. F. Worley, C. A. Barnes, Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J. Neurosci. 20, 3993-4001 (2000).
34. D. J. Sanger, The pharmacology and mechanisms of action of new generation, nonbenzodiazepine hypnotic agents. CNS Drugs 18 (Suppl. 1), 9-15 (2004).
35. N. J. Wesensten, T. J. Balkin, G. L. Belenky, Effects of daytime administration of zolpidem versus triazolam on memory. Eur. J. Clin. Pharmacol. 48, 115-122 (1995).
36. D. Warot, G. Bensimon, P. Danjou, A. J. Puech, Comparative effects of zopiclone, triazolam and placebo on memory and psychomotor performance in healthy volunteers. Fundam. Clin. Pharmacol. 1, 145-152 (1987).
37. T. Kuitunen, M. J. Mattila, T. Seppälä, K. Aranko, M. E. Mattila, Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br. J. Clin. Pharmacol. 30, 453-461 (1990).
38. T. J. Balkin, V. M. O'Donnell, N. Wesensten, U. McCann, G. Belenky, Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 107, 83-88 (1992).
39. H. Allain, A. Patat, A. Lieury, F. Le Coz, C. Janus, G. Menard, J. Gandon, Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur. Psychiatry 10 (Suppl. 3), 129s-135s (1995).
40. T. R. Leufkens, J. S. Lund, A. Vermeeren, Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J. Sleep Res. 18, 387-396 (2009).
41. T. Roehrs, L. Merlotti, F. Zorick, T. Roth, Sedative, memory, and performance effects of hypnotics. Psychopharmacology 116, 130-134 (1994).
42. C. R. Rush, R. R. Griffiths, Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 16, 146-157 (1996).
43. N. J. Wesensten, T. J. Balkin, G. L. Belenky, Effects of daytime administration of zolpidem and triazolam on performance. Aviat. Space Environ. Med. 67, 115-120 (1996).
44. U. Rudolph, F. Crestani, D. Benke, I. Brünig, J. A. Benson, J.M. Fritschy, J. R.Martin, H. Bluethmann, H. Möhler, Benzodiazepine actions mediated by specific g-aminobutyric acidA receptor subtypes. Nature 401, 796-800 (1999).
45. M. M. Savic, D. I. Obradović, N. D. Ugresic, J. M. Cook, P. V. Sarma, D. R. Bokonjić, Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: Differential antagonism by flumazenil and b-CCt. Psychopharmacology 180, 455-465 (2005).
46. B. J.Wiltgen, B. P.Godsil, Z. Peng, F. Saab,H. L. June, M. L. Linn, J. M. Cook, C. R.Houser, T. J.O'Dell, G. E. Homanics, M. S. Fanselow, The a1 subunit of the GABA(A) receptor modulates fear learning and plasticity in the lateral amygdala. Front. Behav. Neurosci. 3, 37 (2009).
47. E. R. Korpi, G. Gründer, H. Lüddens, Drug interactions at GABAA receptors. Prog. Neurobiol. 67, 113-159 (2002).
48. U. Rudolph, H. Möhler, GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 6, 18-23 (2006).
49. R. W. Olsen, W. Sieghart, International Union of Pharmacology. LXX. Subtypes of g-aminobutyric acidA receptors: Classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 60, 243-260 (2008).
50. I. Tobler, C. Kopp, T. Deboer, U. Rudolph, Diazepam-induced changes in sleep: Role of the a 1 GABAA receptor subtype. Proc. Natl. Acad. Sci. U.S.A. 98, 6464-6469 (2001).
51. R. M. McKernan, P. J. Whiting, Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. 19, 139-143 (1996).
52. P. J. Whiting, GABA-A receptor subtypes in the brain: A paradigm for CNS drug discovery? Drug Discov. Today 8, 445-450 (2003).
53. S. Akbarian, M. M. Huntsman, J. J. Kim, A. Tafazzoli, S. G. Potkin, W. E. Bunney Jr., E. G. Jones, GABAA receptor subunit gene expression in human prefrontal cortex: Comparison of schizophrenics and controls. Cereb. Cortex 5, 550-560 (1995).
54. J. M. Fritschy, H. Mohler, GABAA-receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359, 154-194 (1995).
55. T. Ohnuma, S. J. Augood, H. Arai, P. J. McKenna, P. C. Emson, Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: Focus on GABA content, GABAA receptor a-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 93, 441-448 (1999).
56. J. N. Marcus, C. J. Aschkenasi, C. E. Lee, R. M. Chemelli, C. B. Saper, M. Yanagisawa, J. K. Elmquist, Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25 (2001).
57. H. Dietrich, F. Jenck, Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology 212, 145-154 (2010).
58. C. Brisbare-Roch, J. Dingemanse, R. Koberstein, P. Hoever, H. Aissaoui, S. Flores, C. Mueller, O. Nayler, J. van Gerven, S. L. de Haas, P. Hess, C. Qiu, S. Buchmann, M. Scherz, T. Weller, W. Fischli, M. Clozel, F. Jenck, Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155 (2007).
59. E. Akbari, N. Naghdi, F. Motamedi, Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. Behav. Brain Res. 173, 47-52 (2006).
60. E. Akbari, N. Naghdi, F. Motamedi, The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 28, 650-656 (2007).
61. E. Akbari, F. Motamedi, N. Naghdi, M. Noorbakhshnia, The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task. Behav. Brain Res. 187, 172-177 (2008).
62. K. E. Boschen, J. R. Fadel, J. A. Burk, Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats. Psychopharmacology 206, 205-213 (2009).
63. J. Fadel, R. Pasumarthi, L. R. Reznikov, Stimulation of cortical acetylcholine release by orexin A. Neuroscience 130, 541-547 (2005).
64. M. Wu, L. Zaborszky, T. Hajszan, A. N. van den Pol, M. Alreja, Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. J. Neurosci. 24, 3527-3536 (2004).
65. G. Telegdy, A. Adamik, The action of orexin A on passive avoidance learning. Involvement of transmitters. Regul. Pept. 104, 105-110 (2002).
66. S. A. Deadwyler, L. Porrino, J. M. Siegel, R. E. Hampson, Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J. Neurosci. 27, 14239-14247 (2007).
67. S. Aou, X. L. Li, A. J. Li, Y. Oomura, T. Shiraishi, K. Sasaki, T. Imamura, M. J. Wayner, Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral longterm potentiation in rats. Neuroscience 119, 1221-1228 (2003).
68. P. Hoever, S. de Haas, J. Winkler, R. C. Schoemaker, E. Chiossi, J. van Gerven, J. Dingemanse, Orexin receptor antagonism, a new sleep-promoting paradigm: An ascending single-dose study with almorexant. Clin. Pharmacol. Ther. 87, 593-600 (2010).
69. J. J. Renger, S. L. Dunn, S. L. Motzel, C. Johnson, K. S. Koblan, Sub-chronic administration of zolpidem affects modifications to rat sleep architecture. Brain Res. 1010, 45-54 (2004).
70. K. J. Clingerman, L. Summers, Development of a body condition scoring system for nonhuman primates using Macaca mulatta as a model. Lab. Anim. 34, 31-36 (2005).